Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).

Authors

Hope S. Rugo

Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Hope S. Rugo , Joyce O'Shaughnessy , Komal L. Jhaveri , Sara M. Tolaney , Fatima Cardoso , Aditya Bardia , Vikalp Kumar Maheshwari , Sandeep Tripathi , Purnima Pathak , Sina Haftchenary , Peter A. Fasching

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.

First Author: Coralea Kappel

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.

First Author: Joseph J Zhao

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

First Author: Nagi S. El Saghir

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.

First Author: Tomás Pascual